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Abstract
Background: The role of human papillomaviruses (HPV) in the development of squamous cell carcinoma (SCC) has
been established for anogenital lesions but still remains controversial for carcinomas in other sites. The aim of this
study was to determine the α-HPV and β-HPV prevalence and their association with p16 expression, sun exposure,
and clinicopathological findings in patients with Bowen’s disease (BD).
Methods: One hundred sixty nine skin biopsy specimens from 157 immunocompetent patients with
extragenital/extraungual BD were examined for HPV status and p16 expression. The presence of
koilocyte-like changes, solar elastosis and papillomatosis was recorded for each specimen.
Results: BD was diagnosed more often in potentially sun-exposed sites with prevalence 73.6 % and a remarkable
predilection for the head and neck region. High risk α-HPV or β-HPV were detected in 34.7 % of lesions and β-HPV
infections dominated over α-HPV. Higher prevalence of koilocyte-like changes and papillomatosis was found in
HPV-positive specimens but it was not statistically significant. The expression of p16 was detected in 79.8 % of lesions
and displayed no correlation with the HPV status. HPV-positivity tended to be detected more often in sun-protected
sites. Dual infections by α-HPV/β-HPV genera and mixed α-HPV infections were not detected, while 37.5 % of β-HPV
positive specimens were infected by two or more β-HPV genotypes. HPV 9 was significantly associated with mixed
β-HPV infections.
Conclusions: HPV may play an etiological role at least in some SCC in situ arising in extragenital sites. Sunprotected
sites may be more dependent on HPV-mediated co-carcinogenesis than sun exposed areas. The presence of
the p16-expression, papillomatosis or koilocyte-like change is not a reliable marker of HPV infection in SCC in
situ.
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Background
There is increasing evidence supporting the role of human
papillomavirus (HPV) in the development of premalignant
and malignant skin lesions in both immunocompetent
and immunocompromised patients [1]. However, in
contrast to anogenital HPV-associated lesions, where the
oncogenic role of mucosal α-HPV genotypes is well estab-
lished, the role of HPV (especially of genus β-HPV) in
extragenital malignancies of the skin is not entirely under-
stood [2]. This is, at least in part, caused by a highly vari-
able prevalence of HPV-positivity observed in invasive
carcinomas (basal and squamous cell carcinoma) and pre-
malignant squamous skin lesions (such as Bowen’s disease
or actinic keratosis) depending on the ethnicity of the
study population and methods used for the HPV detection
[3–17]. In addition, a relatively high prevalence of β-HPV
infections in the normal skin has been reported for some
populations, although the difference in the presence of
specific β-HPV genotypes has been noted between cutane-
ous squamous cell carcinoma (cSCC) and normal skin
specimens [10]. Nevertheless, the role of β-HPV in skin
carcinogenesis is supported by a strong association
between specific β-HPV genotypes, especially HPV5,
HPV8, HPV14, and HPV20 and the development of cSCC
in patients with epidermodysplasia verruciformis (EV), a
rare autosomal recessive disorder classified as a primary
immunodeficiency [18].
Bowen’s disease (BD) is a form of cSCC in situ (SCCIS),
which was originally described by John Templeton Bowen
in 1912 in sun-protected sites (these lesions were possibly
arsenic-induced) [19]. At the present time, BD is syn-
onymous with non-genital squamous cell carcinoma in
situ on sun-protected as well as sun-exposed sites, histo-
logically characterized by full-thickness dysplasia of the
epidermis, sometimes with involvement of follicular epi-
thelium, similar to that observed in HPV-induced ano-
genital intraepithelial neoplasia [20]. In HPV-associated
carcinomas, viral oncoprotein E7 expressed by high-risk
α-HPV genotypes functionally inactivates the retinoblast-
oma protein (pRb), which in turn leads to the overexpres-
sion of the p16INK4A (p16) tumor suppressor [21] and the
immunohistochemical detection of p16 is often used
as a surrogate marker for the high-risk HPV infection
in squamous cell carcinomas of the vulva, penis, peri-
anal area, uterine cervix and oropharynx [21, 22].
Similarly, the over-expression of p16 was also re-
ported in BD [13, 23–30]; however, only few studies
have focused on a correlation of the expression of
p16 with the HPV status in Bowen’s disease and when
this was performed, a correlation between p16 expres-
sion with the presence of mucosal HPV types only
was studied [13, 23, 24].
In this study we evaluated by the DNA polymerase chain
reactions (PCR) and hybridization the presence of mucosal
(α-papillomavirus genus) and cutaneous/epidermodysplasia
verruciformis (β-papillomavirus genus) HPV genotypes in
169 biopsy specimens from extragenital/extraungual BD
lesions diagnosed in 157 Eastern European Caucasian
immunocompetent patients. In addition, we examined the
association between the presence of α-HPV, β-HPV and
the expression of p16 protein, as well as clinicopathological
patterns and the distribution of specific HPV genotypes in
BD. Our results provide additional insight into the role of
sun-exposure, HPV-infection and development of Bowen’s
disease.
Methods
Patients, tissue specimens and p16 immunohistochemical
staining
After Faculty Hospital in Pilsen Ethical Board approval,
a total of 169 skin biopsy specimens collected between
1996 and 2014 from 157 patients diagnosed with
Bowen’s disease/SCC in situ were randomly retrieved
from the pathology files of Šikl’s Department of Path-
ology in Pilsen, Czech Republic. None of these patients
was diagnosed with an immunosuppressive condition or
treated with immunosuppressive drugs. In all these
cases, the hematoxylin-eosin stained slides were
reviewed to confirm the diagnosis (Fig. 1). The presence
of koilocyte-like changes (Fig. 2), solar elastosis and
papillomatosis (Fig. 3) was recorded for each specimen.
Considering possibility of their different etiological ori-
gin, cases of actinic keratosis, Bowenoid type, were not
included in the study. These cases usually showed at
least focal superficial keratinocyte maturation (the lack
of full-thickness atypia), variable (slight to pronounced)
atypia of the basal layer keratinocytes at the periphery of
the lesion, less defined transition to normal epidermis,
and less frequent follicular and acrosyringeal involve-
ment. Likewise, equivocal cases, which were hard to
classify between Bowen’s disease/SCC and actinic
Fig. 1 Representative case of Bowen’s disease, with full-thickness
involvement of the epidermis by dysplastic keratinocytes. Solar
elastosis and chronic inflammation are present in the superficial
dermis. Hematoxylin-eosin, original magnification × 200
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keratosis, Bowenoid type, were not included. For the de-
tection of p16 by immunohistochemistry (IHC), the
most representative paraffin blocks were selected and
4 μm tissue sections were stained with the p16 antibody
(CINtec® p16 Histology, Ventana) using the Ventana
Benchmark automated stainer, according to the manu-
facturer’s protocol. Appropriate positive and negative
control slides were used. The staining pattern for p16
was classified as positive when showing the “block-type”
diffuse nuclear and cytoplasmic staining (Fig. 4), typic-
ally seen in HPV-induced anogenital intraepithelial
neoplasia. Other staining patterns were classified as p16-
negative and included the following findings: (i) negative
(no positive cells), (ii) equivocal (weak and focal positiv-
ity), and (iii) focal (strong unequivocal positivity in the
minority of tumor cells, typically in a map-like pattern).
Polymerase chain reaction
For molecular-genetic studies, genomic DNA was
isolated from formalin-fixed, paraffin-embedded tissue
using the QIAsymphony DNA Mini Kit (Qiagen,
Hilden, Germany) on QIAsymphony SP device ac-
cording to the manufacturer’s protocol. Special pre-
cautions were taken to prevent contamination of
specimens by the HPV DNA. The quality of isolated
DNA was examined by the PCR reaction that ampli-
fies set of control genes with different amplicon sizes
(100–600 bp) [31].
The detection α-HPV DNA was performed using
multiple PCR primers from the L1, E1, and E6–E7 re-
gions of the HPV genome. In brief, primers GP5
+/GP6+ targeting L1 region of the HPV genome were
used for the standard wide-range detection of muco-
sal HPVs from α- genus. Type-specific PCR detection
of E6-E7 region of the most prevalent six HR-HPV
types, namely types 16, 18, 31, 33, 35, and 45, was
used to increase the sensitivity of detection for muco-
sal high risk (HR) α-HPV genotypes and to avoid
negative findings due to the possible integration of
HPV DNA into the human genome [32].
Cutaneous HPV types were detected by the following
two methods: (i) RHA Kit Skin (beta) HPV assay
(Diassay B.V., Rijswijk, the Netherlands), which is based
on PCR and reverse hybridization of amplified products
on a probe-covered strip, was used to detect clinically
relevant infection of betapapillomavirus genotypes,
namely HPV 5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24,
25, 36, 37, 38, 47, 49, 75, 76, 80, 92, 93 and 96 and (ii)
PCR assay using the CPSGB primers that amplify part of
the E1 region of most mucosal α-HPVs as well as cuta-
neous β- and γ-HPVs [33].
All PCR reactions were run in GeneAmp PCR System
9700 (PE/Applied Biosystem, Forster City, CA). Ampli-
cons were analyzed by electrophoresis in 2 % agarose gel
using ethidium bromide staining. Positive PCR samples
were genotyped by hybridization to the type specific
probes (RHA Kit), or sequenced and compared to the
Fig. 2 Koilocyte-like change in the superficial part of dysplastic
epithelium, characterized by perinulear halo around hyperchromatic
and irregular nuclei. Hematoxylin-eosin, original magnification × 400
Fig. 3 Some Bowen’s disease lesions showed papillomatosis, which
was marked in this case. Hematoxylin-eosin, original magnification
× 50
Fig. 4 Representative case of p16-positive Bowen’s disease showing
diffuse “block-type” nuclear and cytoplasmic p16 staining. Original
magnification × 100
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relevant sequences in the NCBI sequence database (GP5
+/GP6+ and CPSGB based PCR). Positive and negative
controls were included in every single run.
Data processing and statistical analysis
Based on their anatomical location, lesions were classi-
fied as localized in sun-protected (trunk, lower extrem-
ities) or potentially sun-exposed (all other sites),
excluding anogenital and periungual lesions. For the
assessment of anatomical distribution of BD lesions,
body surface area corresponding to these sites was con-
sidered as follows: head and neck: 9 %; upper extrem-
ities: 18 %; trunk: 37 % and lower extremities: 36 % [34].
BD cases that displayed strong diffuse IHC staining
pattern for p16 were coded as p16-positive and all other
staining patterns were coded as p16-negative. From a
molecular standpoint, cases were labeled as HPV-
positive if they displayed positivity for the high risk α-
HPV or at least one of the two tests used for the detec-
tion of β-HPV DNA proved positive. Cases were scored
as HPV negative if all 3 assays for high risk α-HPV as
well as β-HPV genotypes revealed no virus while display-
ing no problems in the quality or quantity of the isolated
DNA.
Upper and lower limits of 95 % confidence intervals
for proportions (CI95) were calculated by Wilson
method with continuity correction [35]. Significance
of differences between sample proportions and hy-
pothesized population proportions was tested using
one-sample z-test. Significance of association between
two categorical classifications was tested by Fisher’s
exact test. The strength of associations between two
binary variables (HPV DNA status and p16 expres-
sion) was determined by phi coefficients using the
package ‘psych’ [36]. in R software [37]. Agreement
between the two assays used for the detection of β-HPV
DNA was determined by Cohen’s kappa coefficient using
the GraphPad QuickCalcs calculator (http://www.graph
pad.com/quickcalcs/). All p-values are two-tailed unless
specified otherwise and the differences were considered as
statistically significant if p < 0.05).
Results
The study group consisted of 157 patients of Cauca-
sian race and Eastern European origin (70 females
and 87 males) previously diagnosed with Bowen’s dis-
ease/SCC in situ. Among them, nine patients devel-
oped multiple BD lesions, which were all included in
this study (7 patients developed 2 lesions, 1 patient 3
lesions, and the remaining patient 4 lesions). The age
at diagnosis (or diagnosis of the first lesion for cases
with multiple neoplasms) ranged from 43 to 96 years
(median: 74 years for both genders; 76 years for
women and 73 years for men). The age at the first
diagnosis was not significantly different between the
male and female patients (p = 0.5972).
From these 157 patients, one or more biopsy speci-
mens corresponding to distinct BD lesions were col-
lected, with a total of 169 biopsy specimens (Additional
file 1). The distribution of BD sites was as follows: head
and neck region: 58.6 %, lower extremities: 14.8 %; upper
extremities: 10.7 %; trunk (chest and back): 10 %; un-
known location (but not anogenital area): 5.9 %. The dis-
tribution of BD lesions with a known location was not
significantly different between male and female speci-
mens. Likewise, no significant differences were identified
for other demographic or clinical factors between male
and female biopsy specimens. (Additional file 1).
BD was diagnosed more often in potentially sun-
exposed sites (in 117 out of 159 lesions with a known
location) with prevalence 73.6 % (CI95: 66.2–79.8 %),
which is significantly higher than 27 % (p < 0.0001; one-
sample z-test) that would be expected under the
assumption of equal disease distribution between sun-
exposed and sun-protected sites (corrected for the
corresponding body surface areas; see Methods sec-
tion) and equal average size of lesions in sun-exposed
and sun-protected sites. The majority of the lesions
from sun-exposed sites are located in the head and
neck region (99/117, 84.6 %), while the head and
neck region represents only about 1/3 of the total
surface of the sun-exposed body area. This indicates a
remarkable predilection of Bowen’s disease for the
head and neck region over other sun-exposed sites
(upper extremities) (p < 0.0001; one-sample z-test).
Solar elastosis was found in 93 of 169 biopsy specimens
(55.0 %; CI95 = 47.5–62.3 %). Among 159 lesions with a
known location, solar elastosis was found in 80/117
(68.4 %; CI95 = 59.7–76.1 %) lesions from sun-exposed
sites but only in 11/42 (26.2 %; CI95 = 15.3–41.1 %) lesions
from sun-protected sites. The difference between these
two proportions is statistically significant (p = 0.0001; Fish-
er’s exact test), which supports the hypothesis that preva-
lence of solar elastosis is higher in sun-exposed sites. This
observation, while somewhat predictable, indicates that
our classification of specimens according to the sun-
exposure status are correct. In both sun-exposed and sun-
protected sites the proportion of BD specimens positive
for solar elastosis is notably lower than 100 %, which sug-
gests that the development of BD may require lower
cumulative sun exposure than solar elastosis.
Among 168 lesions immunohistochemically evaluable
for p16 expression, 134 lesions (79.8 %; CI95 = 73.1–
85.1 %) were scored as p16-positive. Of the remaining
34 lesions scored as p16-negative, 26 lesions displayed
either negative or equivocal/weakly positive staining by
IHC and 8 lesions showed p16-positivity that was un-
equivocal but limited to only a minority of neoplastic
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cells (map-like staining pattern). As a result, p16-
positive cases likely represent the majority of BD cases
in general population, with the true proportion of p16-
positivity in BD cases significantly higher than 50 %
(one-tailed p < 0.0001; one-sample z-test).
DNA from 46 biopsy specimens displayed low quality,
low quantity, or both. Among them, 42 specimens dis-
played negative results for HPV DNA by all of the three
HPV assays used in this study. Due to the low confi-
dence in these negative results, which may in some cases
reflect degradation of analytical target rather than the
true absence of HPV DNA, these 42 specimens were not
considered in further analyses.
Thus, 127 specimens were evaluable for the presence
of α-HPV genotypes, and 13 (10.2 %; CI95 = 6.1–16.7 %)
were found to be α-HPV positive, including 12 speci-
mens (9.4 %; CI95 = 5.5–15.8 %) positive for high-risk α-
HPV genotypes (HPV 16: 6 cases; HPV 33: 2 cases; HPV
18, HPV 56, HPV 58, and HPV 66: 1 case each) and one
case positive for a low-risk α-HPV genotype (HPV 81).
All α-HPV-positive cases (100 %, CI95 = 75.8–100 %) and
93/114 α-HPV-negative cases (81.6 %; CI95 = 73.5–
87.6 %) were found positive for p16 expression by IHC.
Of the seven female patients with BD lesions positive
for high-risk α-HPV, cervical cytology and/or biopsy
specimens from the uterine cervix were available in four
patients. Among them, three patients were negative for
intraepithelial cervical lesions or abnormal cytology and
one was positive for low-grade squamous intraepithelial
lesion (CIN I/LSIL) with high-risk HPV detected by
PCR (HPV genotype was not determined). Consequently,
HR α-HPV-infected BD lesions appear not to be neces-
sarily accompanied with α-HPV-induced cervical lesions.
Positivity for β-HPV genotypes was detected by two
assays, of which RHA Kit Skin (beta) HPV assay, which
combines PCR with DNA hybridization, is expected to
be more specific for β-HPV at clinically relevant viral
loads than E1-based PCR using CPSGB primers (see
Methods section). After exclusion of (i) the 42 HPV-
negative specimens with problematic DNA (see above)
and (ii) 6 cases negative for α-HPV that were found not
evaluable for β-HPV, a total of 121 specimens were eval-
uated for the associations between the combined HPV
status (α and/or β genera) and other variables, such as
sex, sun exposure, p16 status, and the presence of solar
elastosis or koilocyte-like changes (Table 1).
The number of specimens infected by β-HPV geno-
types was found to be 30/120 (25.0 %, CI95 = 18.1–
33.4 %) by the E1-based PCR assay and 19/119 (16.0 %,
CI95 = 10.5–23.6 %) by the RHA Kit Skin (beta) assay.
We have also evaluated the concordance of the results
of the two β-HPV assays on the 119 cases that were
evaluable with both these assays (one case positive by
E1-based PCR assay and negative by RHA Kit Skin
(beta) was not included due to the low quality and quan-
tity of isolated DNA and consequently the low confi-
dence in this negative assay result). Both β-HPV assays
were positive for 19 specimens and negative for 90 spec-
imens, giving 91.6 % observed agreement. The E1-based
assay was able to detect additional 10 positive cases that
had been reported by the RHA Kit as negative. Cohen’s
kappa was determined to be 0.742 (CI95 = 0.594–0.890)
indicating good agreement between these two assays.
For further biomedical interpretation we considered
cases detected by E1-based PCR assay as β-HPV-
positive.
Dual infections with both α-HPV and β-HPV genera were
not observed among 120 specimens evaluable for both α-
HPV and β-HPV statuses. All 12 specimens, which were
found positive for α-HPV genotypes, were β-HPV-negative,
and conversely, all 30 specimens, which were found positive
for β-HPV genotypes, were α-HPV-negative. Assuming that
the distribution of detected α-HPV and β-HPV infections
across these 120 specimens is independent, the probability
of occurrence of dual α-HPV/β-HPV infections could be
estimated as 100 × (12/120) × (30/120) = 2.5 %, and the
binomial probability of finding exactly 0 dual α-HPV/β-
Table 1 Crosstabulation of p16-expression and other findings
based on the HPV DNA status in 121 biopsy specimens
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HPV infections among 120 cases would be p(0) =
0.04792. Considering the relatively low p(0) value, our
data do not support the assumption of independent
occurrence of α-HPV and β-HPV infections and sug-
gest that the dual infections by α-HPV and β-HPV
genera occurs less frequently than expected by
chance, if they occur at all in Bowen disease.
Next, the presence of mixed infections by two or more
genotypes was examined in BD specimens infected
exclusively by α-HPV or β-HPV genera. All of the 13
lesions positive for α-HPV were infected by single virus
genotypes with following distribution: HPV 16: six le-
sions; HPV 33: two lesions; HPV 18, 56, 58, 66 and 81:
one lesion each. In contrast, 16 β-HPV-positive speci-
mens, for which virus genotype could be determined,
displayed the following distribution of the number of
distinct β-HPV genotypes: 10 specimens: 1 genotype; 2
specimens: 2 genotypes; 3 specimens: 3 genotypes, and 1
specimen: 4 distinct β-HPV genotypes. The proportion
of β-HPV-positive specimens infected with multiple β-
HPV types was 37.5 % (CI95 = 18.5–61.4 %) and the aver-
age number of β-HPV genotypes per specimen was
found to be 1.69. Interestingly, all specimens positive for
multiple β-HPV genotypes corresponded to morpho-
logically single BD lesions. The distribution of β-HPV
genotypes detected in these 16 specimens is presented in
Fig. 5a.
In order to assess whether mixed infections by several
β-HPV genotypes occur more often than expected by
chance, we performed permutation test, in which 10.000
permutation replicates were constructed for 16 speci-
mens with the same distribution of β-HPV genotypes as
depicted in Fig. 5a. The proportion of specimens with
two or more distinct β-HPV genotypes in permutation
replicates was found to be 0.485 (77604/160000), which
would correspond to the hypothetical proportion of BD
lesions with mixed β-HPV infections, if the infections by
β-HPV were independent events. The observed propor-
tion of mixed β-HPV infections 0.375 is not significantly
different from the hypothetical proportion 0.485 (z-test
for one proportion, p = 0.3786); therefore, we cannot
reject the hypothesis that β-HPV infections are inde-
pendent events which co-occur as expected by chance.
Intriguingly, however, HPV 9 has been detected in 4
specimens that were all infected by at least one another
β-HPV genotype (Fig. 5b), while HPV 24 has been de-
tected in 3 BD specimens as the only infecting β-HPV
genotype and in 1 BD specimen co-occurring with an-
other genotype (Fig. 5c). The association between the
status of infection (mixed infections vs single infection)
and the presence or absence of HPV 9 is statistically sig-
nificant (two-tailed p = 0.0082, Fisher’s exact test), which
supports the hypothesis that HPV 9 co-occurs in BD
lesions with other β-HPV genotypes more often than
expected by chance. Consequently, HPV 9-positive BD
lesions are more likely to display mixed infections by
several β-HPV genotypes than BD lesions positive for
any β-HPV genotype other than HPV 9 (odds ratio 37.8;
CI95 = 1.493–957.2). In contrast with HPV 9, the associ-
ation between the HPV 24 and the status of infection
(mixed infections vs single infection) is not significant
(two-tailed p = 1.0000, Fisher’s exact test).
P16 expression was found positive in 22/30 (73.3 %,
CI95 = 55.6–85.8 %) of β-HPV positive BD lesions, in-
cluding all 4 specimens positive for HPV 5 or HPV 8,
which have been previously reported by Akgül et al. as
the “high-risk β-HPV genotypes” [38]. However, p16 ex-
pression was also found positive in 67/78 (85.9 %, CI95 =
76.5–91.9) of β-HPV negative BD lesions.
The overall prevalence of HPV-positivity (α and β gen-
era combined) in BD cases in the studied population can
be estimated as 34.7 % (CI95 = 26.8–43.5 %), which is
significantly less than 50 % (one-tailed p = 0.0005). Con-
sequently, the majority of BD cases in the studied popu-
lation are not infected with high risk α-HPV or β-HPV.
The results presented in Table 1 suggest: (i) a higher
prevalence of HPV-positive cases in sun-protected sites
(11/26; 42.3 %) relative to sun-exposed sites (28/87;
32.2 %); (ii) a lower prevalence of solar elastosis in HPV-
positive (21/42; 50 %) relative to HPV-negative (48/79;
60.8 %) specimens; (iii) a higher proportion of specimens
with koilocyte-like changes in HPV-positive (21/42;
50 %) compared to HPV-negative (29/79; 36.7 %) biopsies;
and (iv) a higher proportion of papillomatosis-positive
cases in HPV-positive (17/41; 41.4 %) over HPV-negative
(25/79; 31.6 %) cases. While none of these differences was
found to be statistically significant, some of them are con-
sistent with a biological background and consequently
plausible (e.g. higher prevalence of koilocyte-like changes
or papillomatosis in HPV-positive specimens).
The results demonstrated that there is no appreciable
association between the p16-expression and the HPV
DNA status (phi = - 0.08). The proportions of p16-
positive cases in HPV-negative and HPV-positive BD
specimens were similar (87.1 % vs 80.0 %; p =0.4247).
The datasets supporting the conclusions of this article
are included in Additional file 2.
Discussion
The causative role of β-papillomavirus infection in the
development of extragenital cSCC has been suggested
decades ago [39]; however, it has not yet been widely
accepted. Nevertheless, the growing body of evidence
supports the involvement of β-HPV in the development
of cSCC at least in epidermodysplasia verruciformis
patients and at least indirectly, via the inhibition of UV-
induced apoptosis and/or impaired DNA repair, or other
mechanisms [40]. Consistent with these findings, the
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International Agency for Research on Cancer (IARC)
classified two β-HPV genotypes HPV 5 and HPV 8 as
possibly carcinogenic to humans (all other β-HPV and
γ-HPV genotypes are presently listed as agents “not clas-
sifiable as to their carcinogenicity to humans”) [41].
Results published by other investigators reported a
highly variable prevalence of HPV-positivity in malig-
nant and pre-malignant cutaneous lesions, depending on
the ethnicity and immune status of the study population,
and methods used for the HPV detection [3–17]. Like-
wise, the spectrum of detected HPV genotypes varies
considerably across different studies, which is consistent
with the notion that β-HPV genotypes differ in their
carcinogenicity [40, 41]. Our study is, to the best of our
knowledge, the first study with more extensive sample
size that reports (i) the prevalence of α- and β-
papillomavirus genotypes, (ii) the association of HPV
status with p16 expression, and (iii) the clinicopathologi-
cal findings in β-HPV-positive SCC in situ in Czech
(Eastern European Caucasian) immunocompetent
patients.
The overall prevalence of HR α-HPV and β-HPV posi-
tivity in BD cases, estimated by our study as 34.7 %
(CI95 = 26.8–43.5 %), is consistent with several previous
publications that reported 33–40 % of HPV-positive BD
cases [12, 42, 43]. Likewise, the HPV prevalence of
34.7 % in determined in this study for immunocompe-
tent BD patients is not substantially different from 40 %
of HPV-positivity determined for immunocompromised
BD patients in our previous report (Švajdler et al. Am J
Dermatopathol, 2016, in press). In contrast, other inves-
tigators reported higher prevalence of HPV-positive BD
cases (60–91 %) [5, 7, 8, 16], but all these studies exam-
ined only limited numbers of BD cases (10 to 62). The
difference in HPV prevalence reported by us and other
investigators may also reflect different HPV assay sensi-
tivities and different patient populations. In order to
account for different assay sensitivities we have
employed two different PCR-based assays and found
good inter-assay agreement (91.6 %) with Cohen’s kappa
of 0.742. In addition, for further statistical processing we
used the results from E1-based assay, which detected
more positive cases than RHA Kit Skin (beta) assay and
yet we report lower overall prevalence of HPV in our set
of BD lesions. Consequently, we consider our results to
be reliably reflecting HPV status of BD lesions in our
target Eastern European population. In this study we
found similar HPV prevalence in male and female
Fig. 5 a Distribution of all β-HPV genotypes across 16 β-HPV-positive specimens for which specific β-HPV genotypes could be identified. Full bars:
specimens with 2 or more β-HPV genotypes; empty bars: specimens with single β-HPV genotype. b Status of β-HPV infection (mixed vs single
infection) across specimens with or without detected HPV 9. c Status of β-HPV infection (mixed vs single infection) across specimens with
or without detected HPV 24
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patients (31.3 % vs 35.0 %), which differs from our previ-
ous report that identified higher HPV prevalence in
female relative to male patients; however, this difference
may be related to the different immune statuses of
patient populations under examination.
The median age at BD diagnosis in our set of immuno-
competent patients is 74 years, which is consistent with
73 years reported by a large population-based study of
non-genital BD cases in a European population [44], but
considerably higher than 63.5 years found in our recent
study of immunocompromised East European BD patients
(Švajdler,et al. Am J Dermatopathol, 2016, in press). Conse-
quently, our results support earlier onset of BD in im-
munocompromised patients relative to immunocompetent
patients from the same geographical population.
In our set of HPV-positive BD specimens, the β-
papillomavirus genotypes predominated over α-
papillomavirus genotypes, which is consistent with
previous reports on BD/carcinoma in situ in both
immunocompetent and immunocompromised patients
[5–8, 16, 42, 43]. Nevertheless, α-HPV genotypes were
detected in significant proportion of BD lesions
(~10 % of all BD lesions and ~29 % of HPV-positive
BD lesions), which is in line with seven previous
studies that examined the presence of only α-HPV
genotypes in BD and reported in average 14.7 % of
the HPV-positive BD cases (range 4.8–39 %) [13, 15,
23, 24, 45–47].
In analogy with other viruses, mixed viral infections
may be expected to result from co-infection or super-
infection of susceptible cells with two or more HPV
genotypes [48] and indeed, mixed infections by several
α-HPV genotypes [49, 50] or β-HPV genotypes [10] are
commonly found in various clinical settings. Consistent
with these findings, 37.5 % (CI95 = 18.5–61.4 %) of our
β-HPV positive specimens displayed mixed infections
with 2 or more β-HPV genotypes; however, all 13 BD
lesions positive for α-HPV were infected only by single
α-HPV genotypes. This finding is somewhat conflicting
with previous reports according to which mixed α-HPV
cervical infections were observed in 20–50 % of HPV-
positive women [49], because with such an occurrence
of mixed infections, the probability of finding exactly 13
single α-HPV infections among 13 α-HPV positive biop-
sies would be rather low (0.0122–5.50 %). As a result,
the prevalence of mixed α-HPV infections in α-HPV-
positive BD lesions is likely lower than the reported
prevalence of mixed α-HPV infections in cervical infec-
tions/cervical lesions. This finding may be biologically
relevant, since mixed α-HPV infections of uterine cervix
reportedly increase HPV persistence and oncogenic
potential [51, 52], and this “potentiating effect” appears
to be rarely if ever involved in the cutaneous SCC
carcinogenesis.
Similarly, we have not found among our BD specimens
any lesion with dual infection by α-HPV and β-HPV
genera. This finding supports the conclusion that mixed
α-HPV/β-HPV infections in extragenital/extraungual
Bowen’s disease occur less frequently than would be ex-
pected by chance, if the infections by α-HPV and β-HPV
were independent events not affecting each other. While
mixed α-HPV/β-HPV infections have been previously
reported Bowen’s disease, these findings were limited to
genital [53] and ungual [54] cases which may reflect dif-
ferent environment and susceptibility of target cells to
mixed genera infections. Consequently, mixed α-HPV/β-
HPV infections are unlikely involved in the etiology of
extragenital/extraungual Bowen’s disease in the studied
East European population.
In contrast, we observed mixed infections by several
β-HPV genotypes as relatively frequent finding in BD
lesions (6/16 β-HPV-positive lesions displayed mixed
infections with two or more β-HPV genotypes). This
finding is etiologically interesting, since cSCCs are
reportedly more likely to harbor 3 or more β-HPV geno-
types within the same specimen than sun-protected con-
trol specimens [10]. While statistical analysis could not
reject the hypothesis that β-HPV infections in BD speci-
mens are independent events that co-occur as expected
by chance, our analysis identified HPV 9 as the β-HPV
genotype that tends to occur more often in BD with
mixed β-HPV infections than expected by chance. We
hypothesize that the infection of cells by HPV 9 facili-
tates subsequent infections or co-infections by other β-
HPV genotypes, which may be relevant with respect to
malignant transformation of keratinocytes and warrants
future investigation.
Immunohistochemical p16 detection is often used
as a surrogate marker for the high-risk α-HPV infec-
tions in anogenital or oropharyngeal premalignant
and malignant lesions [21, 22]. In Bowen’s disease,
the overexpression of p16 was reported by several
studies, with proportions ranging from 58 to 100 %
of cases [13, 23–30]. Consequently, the IHC staining
for p16 has been suggested as a useful adjunctive test
to support the diagnosis of BD in diagnostically chal-
lenging cases and to distinguish them from actinic
keratosis or seborrhoeic keratosis [30]. However, these
studies employed highly variable cut-off definitions of
p16-positivity. For instance, when “diffuse” nuclear
and cytoplasmic staining for p16 is classified as posi-
tive, 70–100 % of BD cases were classified as p16-
positive [13, 23, 25, 30], which is consistent with our
finding of 134/168 (79.86 %) p16-positive BD cases.
So far, only few studies have correlated p16 expression
in BD with the HPV status. In the study reported by
Willman et al., 28/32 BD cases (88 %) showed strong dif-
fuse p16 staining (>90 % of cells), while HPV DNA was
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present in only 3/20 cases [23]. Reuschenbach et al.
found diffuse p16-positivity in 38/41 lesions (92.7 %),
but HPV was detected in only 16/41 lesions (39.0 %)
[13]. Likewise, Murao et al. reported strong p16 staining
(>50 % of cells) in 103 of 133 lesions (73.6 %) and HPV-
positivity in only 11 (8.3 %) cases [24]. All 3 studies con-
cluded that p16 overexpression in BD is unrelated to the
HPV status, but they only investigated the presence of
mucosal HPV types. In contrast, both mucosal and cuta-
neous HPV genotypes were considered in our series. We
demonstrated that neither the presence of α-HPV types
nor the presence of β-HPV types correlated with p16-
expression. The exact mechanism responsible for p16
expression in BD is currently unknown. Interestingly,
two studies reported that p16-expression correlated
with the loss of pRb expression [23, 24]. An inverse
pattern of p16 and pRb staining suggests that the p16
overexpression may be a response to the lack of func-
tional pRb, which may be independent on the pres-
ence of high risk HPV.
Recently, Gross et al. demonstrated that the vast
majority of the “multicentric” SCCIS of the “Bowe-
noid” type (and its morphologic variants) showed dif-
fuse p16 staining and suggested that HPV might be
the factor responsible for many of the multicentric
SCCIS in the same way than in multicentric anogeni-
tal SCCIS, in which “skip” areas between normal and
abnormal epithelial cells has been strongly associated
with HPV infections [55]. In our study, many BD le-
sions also showed “multicentric” features as defined
by Gross et al. (including pagetoid spread and well-
defined “skip” areas, Fig. 6). Twenty-one “multi-
centric” (multifocal) BD lesions from nine patients
were examined and found to co-occur generally in
the same anatomical sites, which might suggest com-
mon pathogenesis, such as viral infection. For ten
p16-positive multifocal BD lesions the complete HPV
status was available, and HPV could only be detected
in five lesions. Based on this result, we believe that
p16-positivity in a multifocal or multicentric BD
lesion is not predictive for the presence of HPV.
Koilocyte-like changes and papillomatosis represent
two features that are often present in HPV-associated
lesions, such as verrucas or condylomas. While we
detected these changes more frequently in HPV-positive
than in HPV-negative BD specimens, the differences
between proportions were not statistically significant;
therefore we cannot support these features as reliable
discriminants between HPV-positive and HPV-negative
BD cases.
The mechanisms responsible for HPV driven malig-
nant transformation of cutaneous keratinocytes are not
yet fully understood and further investigation in that
matter is warranted (reviewed by Quint et al [2]). Never-
theless, the epidemiological and experimental evidence
suggests the role of combined effects of ultraviolet radi-
ation, immunosuppression and β-papillomavirus infec-
tion. One of the possible interactions between HPV and
UV can be explained by UV-induced T cell-mediated
local immunosuppression [56] that may decrease the
chances of virus clearance and increase the probabil-
ity of multiple (mixed) HPV infections. This mechan-
ism was supported by reports that found a higher
prevalence of HPV infections in sun-exposed relative
to sun-protected sites [9, 10]; however our results
suggest a lower HPV prevalence in sun-exposed rela-
tive to sun-protected sites. Considering this finding
we speculate that tumor development in sun-
protected areas is more dependent on the co-
carcinogenic effects of β-HPV than in sun-exposed
areas, where the higher doses of UV radiation may be
able to induce malignant transformation even without
HPV-mediated co-carcinogenesis.
Conclusions
In summary, approximately one third of BD lesions in
our Czech (Caucasian Eastern European) population
are HPV-associated. In the HPV-positive lesions β-
HPV genotypes predominated, although high- and
low-risk mucosal HPV types were detected in a sig-
nificant proportion of cases. The presence of the p16-
expression, koilocyte-like change or papillomatosis is
not predictive for the presence of neither α-HPV
types nor β-HPV types in extragenital/extraungual
Bowen’s disease. Our study further supports the hy-
pothesis that HPV infection might serve as an im-
portant co-factor in the carcinogenesis of BD and
cSCC and identifies HPV 9 as a possibly significant
β-HPV genotype with respect to mixed β-HPV infec-
tions and keratinocyte carcinogenesis.
Fig. 6 P16-positive “multicentric” Bowen’s disease showing
well-defined “skip” areas and pagetoid spread (inset). Original
magnification × 60 and × 400 (inset)
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